Nama's AI scorecard currently rates Amphastar Pharmaceuticals Buy (6.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is AMPH's P/E ratio?

Amphastar Pharmaceuticals trades at a trailing price-to-earnings ratio of 8.9.

When does AMPH report earnings?

Amphastar Pharmaceuticals's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $0.69.

What is the AMPH price target?

The median analyst price target from 6 analysts is $21.00, with a range of $20.00 – $30.00.

Is AMPH Shariah compliant?

Nama's AAOIFI-style screen reads Amphastar Pharmaceuticals as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Amphastar Pharmaceuticals (AMPH)

Healthcare · Drug Manufacturers Specialty Generic · NASDAQ

Amphastar Pharmaceuticals (AMPH) is a Healthcare company in the Drug Manufacturers Specialty Generic industry. It has a market capitalization of $1.21B, a trailing price-to-earnings ratio of 8.9 and a free-cash-flow yield of 8.7%. Over the most recent reported fiscal year, revenue declined 1.6% and free cash flow per share fell 25.5%. Nama's AI scorecard rates it Buy, 6.5 out of 10. On 12-month momentum it ranks in the middle band of its market.

AI scorecard

Buy · 6.5/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Middle · +5.4% over 12 months ex. last

Middle fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-57.9%

How far the last close sits under the highest price of the past five years.

Market cap	$1.21B
Trailing P/E	8.9
Price / book	1.6
Price / sales	1.7
FCF yield	8.7%
Dividend yield	—
Gross margin	47.7%
Operating margin	15.7%
Net margin	10.8%
Revenue growth (YoY)	-1.6%
Revenue growth (3-yr annual)	+13.0%
EPS growth (YoY)	-15.8%
FCF/share growth (YoY)	-25.5%
Beta	0.9
Exchange	NASDAQ
Sector	Healthcare
Industry	Drug Manufacturers Specialty Generic

AMPH earnings

Next report: Feb 25, 2027 (Q4 2026, EPS estimate $0.69). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 5, 2026	$1.14	$0.86	+32.6%	—
Q2 2026	Aug 6, 2026	$0.91	$0.61	+49.2%	$183.90M
Q1 2026	May 7, 2026	$0.42	$0.71	-40.9%	$171.17M
Q4 2025	Feb 26, 2026	$0.73	$0.92	-20.6%	$183.10M

AMPH analyst price target

Median target $21.00 from 6 analysts, ranging $20.00 – $30.00.

Drug Manufacturers Specialty Generic peers

Ticker	Company	Market cap	P/E
TAK	Takeda Pharmaceutical	$67.16B	42.0
TEVA	Teva Pharmaceutical Industries	$49.72B	18.0
HLN	Haleon	$40.17B	21.3
ZTS	Zoetis	$32.81B	12.0
UTHR	United Therapeutics	$23.94B	21.2
VTRS	Viatris	$22.87B	7.8
NBIX	Neurocrine Biosciences	$16.66B	16.5
ELAN	Elanco Animal Health	$12.86B	24.3

Explore live AMPH data on Nama Insights →

AMPH FAQ

Is AMPH a buy?: Nama's AI scorecard currently rates Amphastar Pharmaceuticals Buy (6.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is AMPH's P/E ratio?: Amphastar Pharmaceuticals trades at a trailing price-to-earnings ratio of 8.9.
When does AMPH report earnings?: Amphastar Pharmaceuticals's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $0.69.
What is the AMPH price target?: The median analyst price target from 6 analysts is $21.00, with a range of $20.00 – $30.00.
Is AMPH Shariah compliant?: Nama's AAOIFI-style screen reads Amphastar Pharmaceuticals as Not Shariah Compliant. At least one of the three ratios or the industry test failed.